About 4D Molecular Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://4dmoleculartherapeutics.com/
Frequently Asked Questions
What is the 52-week range for FDMT?
The 52-week high is $16.93 and the 52-week low is $6.96.
What is the P/E ratio for FDMT?
The P/E ratio data is currently unavailable.
What is the dividend yield for FDMT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -41.33%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -194.74%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.85.
Analyst Recommendation Trends
Wall Street analyst consensus for FDMT over the last few months:
Latest FDMT News
This is the top biotech stock pick from B Riley Securities
Investing.com -- B. Riley Securities reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics, citing the launch of a Phase 3 trial in diabetic macular edema and encouraging two-year data for its lead gene therapy candidate.
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway
4D Molecular Therapeutics remains a Buy as 4D-150 enters phase 3 for wet AMD/DME, cutting injections up to 87%. Click for more on FDMT stock.
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33
B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating 4D-150 in a treatment-naïve DME populationUpdated 2-year data from SPECTRA Part 1 clinical trial in DME continue to demonstrate a favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction EMERYVILLE, Calif., Sept. 28, 2
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; several other stocks also fell premarket.
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 10:20 AM EDTCompany...
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 5:35 PM EDTCompany ParticipantsDavid Kirn...
This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Analysts upgraded Coinbase, 4D Molecular Therapeutics, Affirm, Chime Financial and Bullish, raising ratings and price targets.
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target
Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The R
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-16 | Bizily Scott | -1,635 | - | - |
| 2026-09-16 | Bizily Scott | -1,635 | $13.65 | $22,318 |
| 2026-09-16 | Bizily Scott | +1,635 | $4.14 | $6,769 |
| 2026-09-14 | Kirn David | -58,333 | $13.903 | $811,004 |
| 2026-09-01 | Bizily Scott | -584 | - | - |
| 2026-09-01 | Bizily Scott | -584 | $14 | $8,176 |
| 2026-09-01 | Bizily Scott | +584 | $6.49 | $3,790 |
| 2026-08-19 | Kirn David | -50,000 | - | - |
| 2026-08-19 | Kirn David | -25,927 | $16.4173 | $425,651 |
| 2026-08-19 | Kirn David | -43,149 | $15.3566 | $662,622 |
| 2026-08-19 | Kirn David | +50,000 | $4.14 | $207,000 |
| 2026-08-17 | Bizily Scott | -1,635 | - | - |
| 2026-08-17 | Bizily Scott | -1,635 | $12.2 | $19,947 |
| 2026-08-17 | Bizily Scott | +1,635 | $4.14 | $6,769 |
| 2026-08-13 | Bizily Scott | -1,635 | - | - |
| 2026-08-13 | Bizily Scott | -1,635 | $12 | $19,620 |
| 2026-08-13 | Bizily Scott | +1,635 | $4.14 | $6,769 |
| 2026-08-04 | Kirn David | -26,842 | $10.2301 | $274,596 |
| 2026-08-03 | Kirn David | -12,415 | $10.0461 | $124,722 |
| 2026-07-10 | Kirn David | -442 | $12.8355 | $5,673 |
| 2026-07-10 | Kirn David | -15,283 | $12.0107 | $183,560 |
| 2026-07-09 | Kirn David | -42,608 | $12.8656 | $548,177 |
| 2026-06-30 | Bizily Scott | -5,752 | - | - |
| 2026-06-30 | Bizily Scott | -814 | - | - |
| 2026-06-30 | Bizily Scott | -6,566 | $14 | $91,924 |
| 2026-06-30 | Bizily Scott | +5,752 | $6.49 | $37,330 |
| 2026-06-30 | Bizily Scott | +814 | $4.14 | $3,370 |
| 2026-06-23 | Bizily Scott | -9,810 | - | - |
| 2026-06-23 | Bizily Scott | -9,810 | $12 | $117,720 |
| 2026-06-23 | Bizily Scott | +9,810 | $4.14 | $40,613 |
| 2026-06-22 | Kirn David | -114,746 | $10.4653 | $1,200,851 |
| 2026-06-17 | Miller-Rich Nancy | +50,000 | - | - |
| 2026-06-17 | GRAY SUSANNAH | +50,000 | - | - |
| 2026-06-17 | THEUER CHARLES | +50,000 | - | - |
| 2026-06-17 | Tomasello Shawn | +50,000 | - | - |
| 2026-06-17 | Chacko Jacob | +50,000 | - | - |
| 2026-06-17 | SBLENDORIO GLENN | +50,000 | - | - |
| 2026-06-17 | MILLIGAN JOHN F | +75,000 | - | - |
| 2026-06-01 | Kirn David | -1,922 | $10.0197 | $19,258 |
| 2026-03-25 | Kirn David | +750,000 | - | - |
| 2026-03-25 | Bizily Scott | +217,000 | - | - |
| 2026-03-25 | Simms Christopher Paul | +219,000 | - | - |
| 2026-03-20 | Gupta Ashoo | -221 | - | - |
| 2026-03-20 | Gupta Ashoo | -865 | - | - |
| 2026-03-20 | Gupta Ashoo | -80 | $8.61 | $689 |
| 2026-03-20 | Gupta Ashoo | +221 | - | - |
| 2026-03-20 | Gupta Ashoo | -310 | $8.61 | $2,669 |
| 2026-03-20 | Gupta Ashoo | +865 | - | - |
| 2026-01-05 | SBLENDORIO GLENN | +45,000 | - | - |
| 2025-12-20 | Gupta Ashoo | -220 | - | - |
| 2025-12-20 | Gupta Ashoo | -866 | - | - |
| 2025-12-20 | Gupta Ashoo | -79 | $8.68 | $686 |
| 2025-12-20 | Gupta Ashoo | +220 | - | - |
| 2025-12-20 | Gupta Ashoo | -310 | $8.68 | $2,691 |
| 2025-12-20 | Gupta Ashoo | +866 | - | - |
| 2025-12-16 | Bizily Scott | -1,635 | - | - |
| 2025-12-16 | Bizily Scott | -1,635 | $10.9 | $17,822 |
| 2025-12-16 | Bizily Scott | +1,635 | $4.14 | $6,769 |
| 2025-12-12 | THEUER CHARLES | -9,333 | - | - |
| 2025-12-12 | THEUER CHARLES | +9,333 | $1.14 | $10,640 |
| 2025-12-09 | Humer Kristian | +480,000 | - | - |
| 2025-11-17 | Bizily Scott | -1,635 | - | - |
| 2025-11-17 | Bizily Scott | -1,635 | $10.59 | $17,315 |
| 2025-11-17 | Bizily Scott | +1,635 | $4.14 | $6,769 |
| 2025-10-24 | Bizily Scott | -1,084 | - | - |
| 2025-10-24 | Bizily Scott | -2,678 | $12 | $32,136 |
| 2025-10-24 | Bizily Scott | +1,084 | $6.49 | $7,035 |
| 2025-10-16 | Bizily Scott | -1,635 | - | - |
| 2025-10-16 | Bizily Scott | -1,635 | $10.17 | $16,628 |
| 2025-10-16 | Bizily Scott | +1,635 | $4.14 | $6,769 |
| 2025-10-09 | Bizily Scott | -2,408 | $10 | $24,080 |